Over a 10-year period, METS-IR effectively predicted CV events among patients with PsA, with values greater than 2.48 at baseline conferring the greatest risk.

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Apremilast treatment in patients with psoriatic arthritis leads to favorable changes in body composition and improves disease ...

Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis. Twenty-four-week results showed Tremfya reduced signs, symptoms and structural progression of the ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Sotyktu significantly improved skin and joint symptoms of psoriatic arthritis and reduced patient-reported disability with no new safety signals. The drug is a first-in-class oral TYK2 inhibitor.

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic arthritis (PsA). The APEX trial has been comparing the drug against placebo ...

Many people suffer from chronic pain conditions, such as arthritis, muscle strains, or sports injuries, which can severely impact daily activities. FIXit Pain Relief addresses these issues by ...

Among a large cohort of young adults with psoriatic arthritis, 38.8% exhibited radiographic evidence of degenerative disc disease. Researchers in Canada conducted a retrospective cohort study to ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, creating a condition that challenges patients and clinicians alike.